Global pharmaceutical R and D spend is increasing rapidly, now topping a staggering $238bn globally. Increased spend, coupled with unpredictable inflation-related price increases and urgency to fast-track breakthroughs in exciting modalities to market means more pressure on procurement to deliver than ever before.

To create much needed visibility on how to combat against mounting risk facing supply and optimize spend, the 7th R and D Sourcing and Procurement in Pharma Summit returns to Boston this May. As the dependable platform uniting 120+ Procurement, Sourcing, Category Management and Clinical Operations personnel, providing the knowledge and networking necessary to stay at the forefront of technology and tactics to drive proactivity, sustainability and profitability in your procurement operations.

As we expand the meeting to two tracks dedicated to Discovery and Preclinical and Clinical procurement, in 2023 you're more comprehensively than ever before gaining intelligence necessary to inform your pipeline's purchasing strategy.

Your Unmissable Highlights for 2023:

Build risk mitigation into supply chains with the pre-identification of bottlenecks to ensure timely allocation of R and D materials in-budget with Novartis

Scale promising cell and gene therapy pipelines to GMP and beyond with compliancy in mind with Atrara Biotherapeutics and Lexeo Therapeutics

Drive efficiencies in early R and D with cost containment and anticipating the needs of scientists to deliver fast-paced programs with Astellas Pharma and Editas Medicine

Establish and maintain robust clinical partnerships with the design of supplier selection metrics and measurement criteria with I-Mab BioPharma and GSK

Expedite R and D through AI and predictive analytics which drive higher success rates in scientific programs with Takeda and UCB

Read on advanced-procurement-in-pharma.com

Continue reading at advanced-procurement-in-pharma.com

Health and Wellness

Facebook Share

Twitter Share

Linkedin Share

Email Share